CNTB trades 805.7% below Wall Street's consensus target of $6.60.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CNTB achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Connect Biopharma Holdings Limited (CNTB) has a Wall Street consensus price target of $6.60, based on estimates from 5 covering analysts. With the stock currently trading at $0.73, this represents a potential upside of +805.7%. The company has a market capitalization of $46M.
Analyst price targets range from a low of $4.00 to a high of $8.00, representing a 61% spread in expectations. The median target of $7.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CNTB trades at a trailing P/E of -0.7x. Analysts expect EPS to grow +8.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ABBVAbbVie Inc. | $514.7B | $291.31 | $308.88 | +6.0% | Buy | 20.9x | 44 |
 REGNRegeneron Pharmaceuticals, Inc. | $93.2B | $904.35 | $887.79 | -1.8% | Buy | 13.4x | 49 |
 ARQTArcutis Biotherapeutics, Inc. | $3.2B | $25.55 | $41.80 | +63.6% | Buy | 61.9x | 12 |
 RXSTRxSight, Inc. | $188M | $4.54 | $7.05 | +55.3% | Hold | — | 12 |
 INCYIncyte Corporation | $24.3B | $119.65 | $137.67 | +15.1% | Buy | 37.3x | 45 |
 PTGXProtagonist Therapeutics, Inc. | $8.5B | $132.04 | $177.25 | +34.2% | Buy | 28.1x | 26 |
 KYMRKymera Therapeutics, Inc. | $10.8B | $131.73 | $141.53 | +7.4% | Buy | — | 27 |
 VTRSViatris Inc. | $23.2B | $19.91 | $21.13 | +6.1% | Hold | 7.9x | 13 |
 CLDXCelldex Therapeutics, Inc. | $2.0B | $29.87 | $66.80 | +123.6% | Buy | — | 20 |
 CRLCharles River Laboratories International, Inc. | $16.3B | $337.52 | $308.36 | -8.6% | Buy | 29.7x | 37 |
Quick answers to the most common questions about buying CNTB stock.
The consensus Wall Street price target for CNTB is $6.6, representing 805.7% upside from the current price of $0.7287. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CNTB has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $6.6 implies 805.7% upside from current levels.
CNTB's current price is $0.7287 with a consensus target of $6.6 (805.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $8 for CNTB, while the most conservative target is $4. The consensus of $6.6 represents the median expectation. These targets typically reflect 12-month expectations.
CNTB is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CNTB stock forecast based on 5 Wall Street analysts shows a consensus price target of $6.6, with estimates ranging from $4 (bear case) to $8 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CNTB, with a "Buy" consensus rating and $6.6 price target (805.7% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CNTB analyst price targets range from $4 to $8, a 61% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6.6 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.